Co-Diagnostics ROA 2017-2025 | CODX
Current and historical return on assets (ROA) values for Co-Diagnostics (CODX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Co-Diagnostics ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-03-31 | $-0.04B | $0.06B | -54.41% |
| 2024-12-31 | $-0.04B | $0.06B | -50.00% |
| 2024-09-30 | $-0.04B | $0.07B | -50.15% |
| 2024-06-30 | $-0.04B | $0.08B | -40.86% |
| 2024-03-31 | $-0.04B | $0.09B | -38.61% |
| 2023-12-31 | $-0.04B | $0.10B | -33.18% |
| 2023-09-30 | $-0.04B | $0.11B | -37.23% |
| 2023-06-30 | $-0.04B | $0.11B | -30.34% |
| 2023-03-31 | $-0.03B | $0.12B | -23.32% |
| 2022-12-31 | $-0.01B | $0.12B | -9.29% |
| 2022-09-30 | $0.02B | $0.15B | 9.38% |
| 2022-06-30 | $0.03B | $0.16B | 18.09% |
| 2022-03-31 | $0.04B | $0.17B | 30.25% |
| 2021-12-31 | $0.04B | $0.16B | 32.80% |
| 2021-09-30 | $0.04B | $0.11B | 48.00% |
| 2021-06-30 | $0.05B | $0.09B | 62.67% |
| 2021-03-31 | $0.05B | $0.08B | 84.55% |
| 2020-12-31 | $0.04B | $0.07B | 92.97% |
| 2020-09-30 | $0.03B | $0.06B | 96.55% |
| 2020-06-30 | $0.01B | $0.04B | 61.54% |
| 2020-03-31 | $-0.01B | $0.02B | -77.42% |
| 2019-12-31 | $-0.01B | $0.00B | -141.18% |
| 2019-09-30 | $-0.01B | $0.00B | -141.18% |
| 2019-06-30 | $-0.01B | $0.01B | -150.00% |
| 2019-03-31 | $-0.01B | $0.01B | -184.62% |
| 2018-12-31 | $-0.01B | $0.00B | -240.00% |
| 2018-09-30 | $-0.01B | $0.00B | -184.62% |
| 2018-06-30 | $-0.01B | $0.00B | -200.00% |
| 2018-03-31 | $-0.01B | $0.00B | -228.57% |
| 2017-12-31 | $-0.01B | $0.01B | -290.91% |
| 2017-06-30 | $0.00B | $0.00B | 0.00% |
| 2017-03-31 | $0.00B | $0.00B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.009B | $0.004B |
| Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. Co-Diagnostics Inc. is based in UT, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $139.155B | 26.10 |
| Elevance Health (ELV) | United States | $84.931B | 10.96 |
| CVS Health (CVS) | United States | $84.554B | 10.51 |
| Cencora (COR) | United States | $57.517B | 20.01 |
| Natera (NTRA) | United States | $23.347B | 0.00 |
| DiDi Global (DIDIY) | China | $22.403B | 23.80 |
| Labcorp Holdings (LH) | United States | $21.878B | 17.75 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.676B | 0.00 |
| Solventum (SOLV) | United States | $12.566B | 13.30 |
| CochLear (CHEOY) | Australia | $12.083B | 0.00 |
| ICON (ICLR) | Ireland | $11.595B | 10.78 |
| Revvity (RVTY) | United States | $11.128B | 19.15 |
| Doximity (DOCS) | United States | $10.714B | 49.60 |
| Viatris (VTRS) | United States | $10.293B | 3.54 |
| Avantor (AVTR) | United States | $9.056B | 13.16 |
| HealthEquity (HQY) | United States | $8.820B | 38.64 |
| Medpace Holdings (MEDP) | United States | $8.700B | 23.11 |
| Sonic Healthcare (SKHHY) | Australia | $8.407B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.136B | 13.98 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.085B | 24.06 |
| BrightSpring Health Services (BTSG) | United States | $3.934B | 36.10 |
| Sotera Health (SHC) | United States | $3.105B | 17.65 |
| Alignment Healthcare (ALHC) | United States | $2.849B | 0.00 |
| Concentras Parent (CON) | United States | $2.676B | 15.47 |
| Organon (OGN) | United States | $2.568B | 2.73 |
| Surgery Partners (SGRY) | United States | $2.542B | 33.06 |
| PACS (PACS) | United States | $2.027B | 0.00 |
| Progyny (PGNY) | United States | $1.856B | 40.85 |
| Ardent Health (ARDT) | United States | $1.854B | 7.90 |
| GeneDx Holdings (WGS) | United States | $1.838B | 70.80 |
| Premier (PINC) | United States | $1.834B | 13.92 |
| GoodRx Holdings (GDRX) | United States | $1.600B | 32.00 |
| Teladoc Health (TDOC) | United States | $1.230B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.147B | 8.73 |
| Establishment Labs Holdings (ESTA) | $1.100B | 0.00 | |
| CareDx (CDNA) | United States | $1.060B | 16.55 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.902B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.856B | 8.01 |
| QDM (QDMI) | Hong Kong, SAR China | $0.758B | 0.00 |
| LifeMD (LFMD) | United States | $0.684B | 0.00 |
| Nutex Health (NUTX) | United States | $0.661B | 10.01 |
| Embecta (EMBC) | United States | $0.569B | 3.83 |
| InnovAge Holding (INNV) | United States | $0.512B | 0.00 |
| SBC Medicals (SBC) | United States | $0.482B | 0.00 |
| Enhabit (EHAB) | United States | $0.473B | 38.92 |
| Auna S.A (AUNA) | Luxembourg | $0.459B | 10.33 |
| Sonida Senior Living (SNDA) | United States | $0.454B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.449B | 0.00 |
| Omada Health (OMDA) | $0.399B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.267B | 0.00 |
| Oncology Institute (TOI) | United States | $0.212B | 0.00 |
| Beauty Health (SKIN) | United States | $0.184B | 0.00 |
| DocGo (DCGO) | United States | $0.165B | 27.00 |
| Pheton Holdings (PTHL) | China | $0.119B | 0.00 |
| So-Young (SY) | China | $0.102B | 0.00 |
| KindlyMD (NAKA) | United States | $0.084B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.053B | 0.00 |
| ModivCare (MODV) | United States | $0.052B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Biodesix (BDSX) | United States | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.034B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.011B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |